In April, Chimigen was awarded a place in the "2026 Chengdu Hard-Tech Enterprise Poker Deck" as a featured Hard-Tech Enterprise (Hearts).
In May, Chimigen was ranked among the Top 15 Emerging Innovative Pharmaceutical Companies in China 2025.
In July, KMV002, a universal prostate cancer immunotherapy, received FDA clearance for clinical trials.
In July, Chimigen was listed on the China Potential Unicorn Enterprises List.
In September, KMV002 initiated its clinical study and completed dosing of the first patient.
In January, the company was honored on Deloitte China's "Rising Star" list.
In April, the company was awarded the Third Prize at the 2025 "Rong Piao Cup" Innovation Competition.
In May, SN2001 received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA).
In December，Completed Pre-Series A financing exceeding RMB 100 million.
In May, the company was selected as one of the first batch of enterprises on the "Golden Panda Future Star" list in Chengdu High-Tech Zone.
In July, the company was recognized as a Specialized, Sophisticated, Distinctive, and Innovative Small and Medium-sized Enterprise in Sichuan Province and won the Excellence Award at the 9th "Maker China" Pharmaceutical and Health Small and Medium-sized Enterprises Innovation and Entrepreneurship Competition.
In September, the Guangzhou subsidiary was established and moved into the BeiGene Innovation Center (BIC).
In July, Launched ChimiVac (u.s.Subsidiary) in NewYork.
In June, ChimigenBio was founded in the Tianfu International Bio-Town.
In November, the company completed an angel round of financing exceeding RMB 100 million.
Chimigen Biomedical (Chengdu) Co., Ltd.
1601, Tower F2, Chengdu Tianfu International Bio-Town, Chengdu, Sichuan
Tel：028-60610771
E-mail：contact@chimigen.com
Copyright© 2025 Chimigen Biomedical (Chengdu) Co., Ltd.
